IP Library Granted Patent US 8,147,825
Granted Patent B2
US 8,147,825 · App. 10/597,378 · Granted Apr 3, 2012

Topical co-enzyme Q10 formulations and methods of use

Assignee: University of Miami
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,147,825
App. No.
10/597,378
Granted
Apr 3, 2012
Kind
B2
Abstract

Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.

Claims (19)

1. A method of treating melanoma in a subject, comprising topically applying for at least 30 days a 1 to 15% w/w composition of Coenzyme Q10 to the site of the melanoma in an amount effective to reduce the growth of the melanoma.

2. The method of claim 1 , wherein the composition comprising Coenzyme Q10 is administered with an additional anti-cancer agent.

3. The method of claim 2 , wherein the additional agent is an anti-angiogenic agent.

4. The method of claim 2 , wherein the additional anti-cancer agent is co-administered with the composition comprising Coenzyme Q10 to the subject.

5. The method of claim 2 , wherein administration of the additional anti-cancer agent precedes administration of the composition comprising Coenzyme Q10 to the subject.

6. The method of claim 2 , wherein administration of the additional anti-cancer agent follows administration of the composition comprising Coenzyme Q10 to the subject.

7. The method of claim 1 , wherein the additional anti-cancer agent is a chemotherapeutic agent.

8. The method of claim 7 , wherein the chemotherapeutic agent is selected from the group consisting of cyclophosphamide, taxanes, busulfan, methotrexate, daunorubicin, doxorubicin, melphalan, and cladribine.

9. The method of claim 7 , wherein the chemotherapeutic agent is selected from the group consisting of vincristine, vinblastine, chlorambucil, tamoxifen, taxol, camptothecin, actinomycin-D, mitomycin C, and combretastatin.

10. The method of claim 7 , wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, etoposide, verapamil, and podophyllotoxin.

11. The method of claim 7 , wherein the chemotherapeutic agent is 5-fluorouracil.

12. The method of claim 1 , wherein the subject is human.

13. The method of claim 1 , wherein the composition comprising Coenzyme Q10 is formulated as a topical cream.

14. The method of claim 1 , wherein the composition comprising Coenzyme Q10 is liposomal.

15. The method of claim 1 , wherein the composition comprises 1% to 10% w/w of Coenzyme Q10.

16. The method of claim 1 , wherein the composition comprises 1% to 5% w/w of Coenzyme Q10.

17. The method of claim 1 , wherein treatment results in an increase in apoptosis of melanoma cells in the subject.

18. The method of claim 1 , wherein treatment results in inhibition of melanoma-mediated angiogenesis in the subject.

19. A method of treating melanoma in a subject, comprising topically applying for at least 30 days a 1 to 15% w/w composition of Coenzyme Q10 in an amount of no more than 4.0 mg per kg of body weight to the site of the melanoma effective to reduce the growth of the melanoma.

Assignments (3)
SECURITY INTEREST Recorded Aug 29, 2025
From: BPGBIO INC.
To: BERG SURVIVOR’S TRUST; BERG, KARA ANN; THLIVERIS, ANDREW T.
Reel/Frame 072805/0303 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 8147825 WAS ADDED PREVIOUSLY RECORDED AT REEL: 70903 FRAME: 693. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Apr 30, 2025
From: BPGBIO INC.
To: PHOENIX GENESIS LLC
Reel/Frame 071285/0001 →
SECURITY INTEREST Recorded Apr 21, 2025
From: BPGBIO INC.
To: PHOENIX GENESIS LLC
Reel/Frame 070903/0693 →
Continuity (2)
Provisional Application 60538319 · Jan 22, 2004
Related Publication 20080299100A1 · Dec 4, 2008